<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01007019</url>
  </required_header>
  <id_info>
    <org_study_id>YCD142 (YH4808-101)</org_study_id>
    <nct_id>NCT01007019</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects</brief_title>
  <official_title>A Dose-block Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dosing, Dose-escalation Phase I Clinical Trial to Investigate the Safety/Tolerability and PKs/PDs of YH4808 After Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      First in human study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the safety and tolerability, pharmacokinetics/pharmacodynamics (PK/PD)
      parameters of an escalating, single dose/repeat doses of YH4808 in healthy subjects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the PKs, PDs, safety and tolerability of escalating, single/multiple oral doses of YH4808</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>YH4808 30mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 30mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 50mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 400mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 100mg(repeat doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Repeat doses
2.12 volunteers were administered YH4808 100mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 200mg(repeat doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Repeat doses
2.16 volunteers were administered YH4808 200mg or active/placebo comparators.(YH4808:active:placebo=8:6:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 400mg(repeat doses)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Repeat dose
2.12 volunteers were administered YH4808 400mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 600mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH4808 800mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Single dose
2.12 volunteers were administered YH4808 800mg or active/placebo comparators.(YH4808:active:placebo=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 30mg</intervention_name>
    <description>YH4808 30mg (single dose)</description>
    <arm_group_label>YH4808 30mg</arm_group_label>
    <other_name>YH4808 30mg (single dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 50mg</intervention_name>
    <description>YH4808 50mg (single dose)</description>
    <arm_group_label>YH4808 50mg</arm_group_label>
    <other_name>YH4808 50mg (single dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 100mg</intervention_name>
    <description>YH4808 100mg (single dose)</description>
    <arm_group_label>YH4808 100mg</arm_group_label>
    <other_name>YH4808 100mg (single dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 200mg</intervention_name>
    <description>YH4808 200mg (single dose)</description>
    <arm_group_label>YH4808 200mg</arm_group_label>
    <other_name>YH4808 200mg (single dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808</intervention_name>
    <description>YH4808 400mg (single dose)</description>
    <arm_group_label>YH4808 400mg</arm_group_label>
    <other_name>YH4808 400mg (single dose)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 100mg (repeat dose)</intervention_name>
    <description>YH4808 100mg (repeat dose)</description>
    <arm_group_label>YH4808 100mg(repeat doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 200mg (repeat dose)</intervention_name>
    <description>YH4808 200mg (repeat dose)</description>
    <arm_group_label>YH4808 200mg(repeat doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 600mg</intervention_name>
    <description>YH4808 600mg</description>
    <arm_group_label>YH4808 600mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 800mg (single dose)</intervention_name>
    <description>YH4808 800mg (single dose)</description>
    <arm_group_label>YH4808 800mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH4808 400 mg (repeat doses)</intervention_name>
    <description>YH4808 400 mg (repeat doses)</description>
    <arm_group_label>YH4808 400mg(repeat doses)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 volunteers will be administered matched placebo.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>10 volunteers will be administered matched placebo.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40mg</intervention_name>
    <description>24 volunteers will be administered Esomeprazole 40mg</description>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <other_name>24 volunteers will be administered Esomeprazole 40mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers in the age between 20 to 45 years old

          -  Subjects who were determined to be appropriate through screening

          -  Weight: over 50kg, within Â±20% of ideal body weight

          -  Subjects who signed written consent after receiving thorough explanation on trial
             purpose, content, and characteristics of investigational drug

        Exclusion Criteria:

          -  Clinically significant disorder in liver, kidney, cardiovascular, respiratory system,
             endocrine system and CNS in the physical examination and clinical laboratory tests or
             a medical history of malignant tumor or psychological disease

          -  Medical history of gastrointestinal disease or acid restraining surgery,
             gastric/esophagus surgery (excluding appendectomy, hernia surgery)

          -  A history of hypersensitivity to drugs or clinically significant allergic disease

          -  Clinically significant abnormal values in blood chemistry(â¥ 1.5 fold of normal upper
             limit in the levels of SGOT, SGPT)

          -  Subjects who were unable to be applicable for pH meter catheter

          -  Subjects who had a history of drug abuse or who had a positive results on urine drug
             screening

          -  Subjects who had taken usual dose of any prescription drugs within 14 days before the
             treatment or who had used usual dose of OTC drugs within 7 days before the
             treatment(cf, be able to be enrolled in this study according to an investigatory
             consideration)

          -  Subjects who participated in another clinical trial within 3 months before enrolling
             in this study

          -  Subjects who donated whole blood within 2 months or component blood within 1 month or
             who are donated within 1 month before the treatment

          -  Subjects who drank Over 21 units/week of alcohol or subjects who weren't able to stop
             drinking alcohol during the hospitalization

          -  Subjects who stopped smoking within 3 months before the treatment

          -  Subjects who had a beverage containing grapefruits within 24hrs before the
             hospitalization or who had a beverage containing grapefruits during the
             hospitalization

          -  Subjects who had a beverage containing caffeine during the hospitalization

          -  H.pylori positive results on the Urease breath test(Only repeat doses)

          -  Subjects with clinically significant observations considered as unsuitable based on
             medical judgment by investigators
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyung-Sang Yu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical trials center, Seoul national university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 2009</study_first_submitted>
  <study_first_submitted_qc>November 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2009</study_first_posted>
  <last_update_submitted>July 8, 2014</last_update_submitted>
  <last_update_submitted_qc>July 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety, tolerability and PK/PD</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

